OncoCyte Corporation
NASDAQ:OCX
3.2 (USD) • At close June 17, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | OncoCyte Corporation |
| Symbool | OCX |
| Munteenheid | USD |
| Prijs | 3.2 |
| Beurswaarde | 91,517,760 |
| Dividendpercentage | 0% |
| 52-weken bereik | 1.922 - 4.75 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Joshua Riggs |
| Website | https://oncocyte.com |
An error occurred while fetching data.
Over OncoCyte Corporation
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)





